SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: A corporate building overlooking a freew
Business
Alexis Borisy and Co. Raise $520M for New Model VC
Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding.
February 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Nitpicker/Shutterstock
Drug Development
BMS and 2seventy bio Position BCMA CAR-T Therapy for Earlier Treatment
Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal Phase III trial of Abecma in multiple myeloma patients who had received two to four prior lines of therapy.
February 13, 2023
 · 
3 min read
 · 
Kate Goodwin
Courtesy of Abbvie Inc.
AbbVie Braces for Impact as Humira Biosimilars Hit the Market
AbbVie has officially reached the Humira cliff, and 2023 estimates are feeling the effects. The Illinois-based biopharma shared its Q4 and full-year 2022 results Thursday morning.
February 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Garuda Grabs Another $62M for Off-the-Shelf Stem Cell Therapies
Garuda Therapeutics closed a $62 million Series B round Tuesday to support its off-the-shelf, self-renewing blood stem cell technology.
February 8, 2023
 · 
2 min read
 · 
Kate Goodwin
John Tlumacki/The Boston Globe via Getty Images
Drug Development
Biogen’s $1.5B Bet for Depressive Disorders Heads to FDA (Updated)
Biogen and its partner, Sage Therapeutics, announced the FDA has accepted the New Drug Application for zuranolone and granted it priority review in two mental health indications.
February 6, 2023
 · 
2 min read
 · 
Kate Goodwin
simonkr_Getty Images
Drug Development
Novel Biomarkers could Guide New Alzheimer’s Therapies
The discovery of novel Alzheimer’s biomarkers is enabling better trial selection, earlier pipeline decision making and new targets for therapeutics.
February 3, 2023
 · 
4 min read
 · 
Kate Goodwin
Pictured: Financing concept/Getty Images
Unphased by Bear Market, Structure Goes Big with $161.1M IPO
Structure Therapeutics expects to bring in $161.1 million from an upsized IPO, announced Friday.
February 3, 2023
 · 
1 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Patient Square Touts Record-Breaking $3.9B Inaugural Fund
Patient Square Capital announced a record-breaking inaugural fund totaling $3.9 billion, proving even in an unstable economy, there’s still money to be made.
February 2, 2023
 · 
1 min read
 · 
Kate Goodwin
Harold Cunningham/Getty Images
Drug Development
Huntington’s Program Bites the Dust as Novartis Cleans House
Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.
February 1, 2023
 · 
1 min read
 · 
Kate Goodwin
Vera CEO and founder Marshall Fordyce, M.D./courte
Drug Development
Vera Doubles Down on IgAN Data with 36-Week Analysis (Updated)
Vera Therapeutics released a 36-week per-protocol analysis of the Phase IIb trial assessing atacicept in IgA nephropathy.
January 30, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy Getty Images
Study Predicts Higher Prevalence of VEXAS Syndrome (Updated)
A study published Tuesday in JAMA revealed VEXAS, a little-known syndrome with a high mortality rate, has a higher prevalence than previously thought.
January 26, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Business
As Tech Giants Fall, Tech-Focused VC Fund Rakes in $350M
Three venture capitalists debuted Dimension I Wednesday, a new fund with $350 million to fuel modern biotech.
January 25, 2023
 · 
1 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Drug Development
Rhythm’s Imcivree Improves Quality of Life in Bardet-Biedl Syndrome (Updated)
Rhythm Pharmaceuticals published data Monday showing Imcivree (setmelanotide) improved quality of life for patients with obesity related to Bardet-Biedl Syndrome.
January 23, 2023
 · 
2 min read
 · 
Kate Goodwin
Pat Greenhouse/The Boston Globe via Getty Images
Business
Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated)
Sanofi licensed CytoReason’s inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.
January 23, 2023
 · 
3 min read
 · 
Kate Goodwin
Sarah Silbiger/Getty Images
FDA
Seagen Snags Accelerated Approval in Aggressive Colon Cancer
The FDA granted Seagen’s tyrosine kinase inhibitor Tukysa accelerated approval for an aggressive form of colorectal cancer Thursday.
January 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More